William Blair analyst Andrew Brackmann has reiterated their bullish stance on HOLX stock, giving a Buy rating on July 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Buy rating due to a combination of factors that suggest Hologic is poised for growth. The company’s recent fiscal third-quarter results exceeded expectations, and its revenue guidance for fiscal 2025 has been slightly raised. Management’s insights into demand trends in key segments indicate a positive outlook for revenue and earnings growth, which is crucial for the stock’s upward movement.
Moreover, the breast health business is showing signs of recovery, and other segments like molecular diagnostics are experiencing solid growth. External risks, such as tariffs and macroeconomic conditions in China, appear to be less threatening than anticipated. With the stock trading below its 10-year average and potential for multiple expansion, Brackmann is confident in Hologic’s ability to drive growth, supporting his Buy rating.
In another report released on July 23, TR | OpenAI – 4o also upgraded the stock to a Buy with a $72.00 price target.